Researchers found that a new treatment called nomlabofusp may help increase levels of a protein called frataxin in people with Friedreich’s ataxia (FA), a rare genetic disorder that affects movement and coordination. This increase was observed not only in critical organs but also in easily accessible tissues like skin and mouth cells. The findings suggest that monitoring frataxin levels in these peripheral tissues could serve as a reliable way to track treatment effectiveness.

For those looking to age well, this discovery could be significant. Friedreich’s ataxia is associated with muscle weakness, loss of coordination, and other debilitating symptoms. If nomlabofusp proves effective, it could potentially slow disease progression and improve quality of life for individuals with FA. The research indicates that increases in frataxin levels correlate strongly across different tissues, which could lead to more effective monitoring of treatment outcomes.

The evidence comes from both animal studies and early human trials. While the preclinical data from mice, rats, and non-human primates show consistent results, the human data is still in the early stages. The treatment has not yet been widely tested in larger human trials, so while the results are promising, they are not yet conclusive. Larimar Therapeutics plans to submit their findings to the U.S. Food and Drug Administration (FDA) for potential accelerated approval, but more research is needed to fully understand the treatment’s benefits and risks.

If you or someone you know is affected by Friedreich’s ataxia, staying informed about new treatments like nomlabofusp is important. Consult with healthcare providers about emerging therapies and consider participating in clinical trials if eligible, as they can provide access to cutting-edge treatments while contributing to valuable research.

Source: globenewswire.com